Bufexamac in the treatment of skin diseases in general practice.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D003877:Dermatitis, Contact / Q000188:drug therapy; D005194:Family Practice; D005260:Female; D006801:Humans; D006877:Hydroxamic Acids / Q000031:analogs & derivatives* / Q000627:therapeutic use; D007223:Infant; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000627:therapeutic use; D011538:Pruritus Ani / Q000188:drug therapy; D011539:Pruritus Vulvae / Q000188:drug therapy; D012871:Skin Diseases / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D006877:Hydroxamic Acids; D010648:Phenylacetates